Kornimate/medical-research-clean huggingface dataset:
a study of sb-742457, added to donepezil for the treatment of mild-to-moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the study is designed to investigate the safety and efficacy of sb-742457 when added to stable donepezil treatment in subjects with mild-to-moderate alzheimer's disease.


Eligibility criteria:
inclusion criteria: * subjects and their caregivers must provide informed consent prior to study entry. * subjects must have a clinical diagnosis of probable mild-to-moderate alzheimer's disease with no evidence of disorders that are thought to be the cause of, or contributing to the severity of the subject's dementia and a documented history of at least 6 months of ongoing donepezil therapy with stable dosing for at least the last 2 months. * subjects must have a regular caregiver who is willing to attend visits, oversee the subject's compliance with the study and report on the subject's status. * female subjects of child-bearing potential must agree to abstinence or an approved form of birth control. * subjects must have adequate blood pressure and laboratory values. exclusion criteria: * subjects with a diagnosis of possible, probable or definite vascular dementia may not participate. * subjects with known hypersensitivity to sunlight or a history of seizures, previous exposure to sb-742457, taking agents for which there is a theoretical risk of interaction with sb-742457, or taking medication for alzheimer's disease or centrally acting agents which might impact study outcomes may not participate.

Keywords: alzheimer's disease cognition sb-742457
extracorporeal shock wave therapy on spastic equinus foot in stroke patients

Conditions: Stroke; Equinus Deformity; Spasticity, Muscle

Summary: the goal of this study is to evaluate long term effects of focused extracorporeal shock wave therapy (feswt) on triceps surae spasticity in stroke patients according to the number of sessions applied. hypothesis: 3 sessions of feswt on equinus foot in stroke patients improve spasticity and functionality for longer term than 1 session of feswt.

spasticity is a common complication as a consequence of suffering a stroke and one of the most important causes of disability in this pathology. global data estimate that 12 million people world-wide suffer from spasticity of the upper or lower limb. equinus foot is the most common pattern of the lower extremities. previous studies have reported that extracorporeal shock wave therapy (eswt) is a safe and noninvasive alternative treatment for spasticity. although the authors have shown a beneficial clinical effect of the eswt, outcomes and duration of effect varied across studies. this is a prospective randomized controlled trial. 60 stroke patients with spastic equinus foot post stroke will enroll in this study. the participants will be randomly divided into two groups. the first group (control group) will receive 1 session of feswt, while the second group (experimental group) will receive 3 sessions of feswt, once a week, for 3 consecutive weeks. therapy will be administered directly to the muscle bellies of the gastrocnemius medial and lateral and soleus. the muscle belly will be located by ultrasonography. the primary outcome is modified ashworth scale. secondary outcomes are passive range of ankle motion, mobility and balance test, spasm frequency scale and quality of life scales. participants will be evaluated by the same researcher before the first shock wave therapy and after the last session of feswt will be done periodic revisions on weeks 1, 4, 8, 12, 20, 24, 36 and 48. adverse events will be monitored during the study.

Eligibility criteria:
inclusion criteria: * age greater than 18 years old * time from stroke (ischemic o hemorrhagic) onset of at least 6 months * spastic equinus foot: triceps surae tone grade at least 1+ on the mas score * ability to walk alone with or without aids exclusion criteria: * fixed ankle joint contracture * severe medical problems * treatment of the affected leg with botulinum toxin in the las 6 months * cognitive impairment

Keywords: stroke equinus deformity extracorporeal shock wave therapy
diagnostic performance of [18f]psma-1007 pet/ct imaging in patients with newly-diagnosed prostate cancer

Conditions: Prostate Cancer

Summary: this study assess the diagnostic performance of \[18f\]psma-1007 pet/ct imaging in patients with newly-diagnosed high-risk or very-high-risk prostate cancer


Eligibility criteria:
inclusion criteria: 1. the patient (male) is aged 18 years or above. 2. the patient is able to understand the information presented to him concerning the nature, scope, and consequences of the trial as set out in the information provided to the patient and has provided written informed consent to participate. 3. the patient has newly diagnosed, biopsy-proven, clinically localized prostate adenocarcinoma, and curative prostatectomy with extended pelvic lymph node dissection is his preferred course of treatment. 4. the patient has at least high-risk disease as defined by the nccn guidelines (version 1.2023). that is, the presence of any one or more of the following: * overall isup grade group 4 or 5, * clinical category t3a or greater, * serum psa level greater than 20 ng/ml. 5. the patient has undergone conventional imaging (ct or mri, and bone scan if clinically indicated) to detect the presence of pelvic nodal involvement and bone or visceral metastases within 60 days of the planned pet-ct procedure. exclusion criteria: 1. patients for whom radical prostatectomy is not clinically appropriate or the patient is otherwise unlikely to undergo radical prostatectomy with extensive pelvic lymph node dissection. 2. the patient has received any therapy - be it radiation, surgical or drug therapy - for his prostate cancer. 3. the patient has any contraindication(s) for and/or known hypersensitivity to any constituent(s) of \[18f\]psma-1007. 4. the patient is not able to have pet-ct scans (for example, because of weight, claustrophobia, or inability to lie still for the duration of the scan). 5. the patient is closely affiliated to the investigation site; e.g. is a first-degree relative of the investigator. 6. at the time of screening, the patient is receiving any other investigational agent(s), or he has received any such agent(s) within the previous 30 days, or he is scheduled to receive any such agent(s) in the period up to the planned date for the last study visit. 7. the patient has previously been enrolled in this trial. 8. the patient has previously undergone pet imaging with any psma-avid product. 9. the patient has histological evidence of small-cell carcinoma of the prostate. 10. the patient is clinically unstable or requires emergency treatment. 11. the patient has any mental condition rendering him incapable of understanding the nature, scope, and consequences of the trial as set out in the information given to the patient.
study of hypo-fractionated neoadjuvant radiotherapy for locally advanced gastric cancer

Conditions: Gastric Cancer; Chemoradiation

Summary: gastric cancer is one of the most common malignant tumors in china, and the incidence and mortality rate are second in malignant tumors. the treatment of gastric cancer need integrated multidisciplinary treatment, and surgery is the only possible curative method for gastric cancer at present. previous studies have reported that neoadjuvant chemoradiotherapy can downstage primary tumor to increase radical resection rate in order to improve the long-term prognosis of advanced gastric cancer. however, there is no study on the application of hypo-radiotherapy to neoadjuvant radiotherapy in gastric cancer. the aim of this study was to observe the maximum tolerated dose (mtd) and dose limited toxicity (dlt) of hypo-fractionated radiotherapy for locally advanced gastric cancer.

after enrolled in this study, the patient was first treated with radiotherapy, concurrent with oral s-1 80mg/m2/day, on radiotherapy days. 3 weeks after the end of radiotherapy, patients treated with neoadjuvant chemotherapy with oxaliplatin and s-1. oxaliplatin is given on dose of 130mg/m2 iv on day 1; s-1 on 40-60mg po bid on day 1-14, oral. imaging evaluation was performed 3 weeks after neoadjuvant treatment. the radical operation and surgical procedure were determined on mdt discussion. non-operable patients continue with 3 cycles of chemotherapy, and the chemotherapy regimen can be changed. a 3 cycle of sox adjuvant chemotherapy was performed after surgery.

Eligibility criteria:
inclusion criteria: * clinical stage t3-4n+m0 * gastric cancer or siewert ii/iii esophagogastric junction carcinoma; * pathologically confirmed adenocarcinoma; * 18-75 years old, male or female; * karnofsky score \>= 70; * white blood cell count \>= 4 x 109 / l; platelet count \>= 100 x109/l; serum creatinine =\< 1 x upper limit of normal, total bilirubin =\< 1 x upper limit of normal, alanine aminotransferase and aspartate aminotransferase =\< 2.5 x upper limit of normal, alkaline phosphatase =\< 5 x upper limit of normal. exclusion criteria: * any chemotherapy or radiotherapy history before enrollment * siewert i egj cancer

Keywords: gastric cancer chemo-radiotherapy phase i study hypo-fractionated radiotherapy
laser lithotripsy for ureteral stones

Conditions: Ureteric Stone

Summary: objectives: to present the outcomes of retrograde and antegrade ureteroscopic laser lithotripsy in the treatment of proximal ureteral stones ranging in size from 10 to 20 millimeters in diameter. patients and methods: from march 2023 to december 2023, 70 patients were included in this prospective randomized double-arm interventional study. patients were divided into two groups: group 1: (35 patients) had semi-rigid retrograde ureteroscopic laser lithotripsy and group 2: (35 patients) had semi-rigid antegrade ureteroscopic laser lithotripsy.

the present study was conducted in al-azhar university hospital (damietta branch), urology department,at the period from march 2023 to december 2023. seventy patients with symptomatic proximal medium sized ureteric stones were classified in two groups retrograde uretroscopic laser lithotripsy (group 1) and antegrade ureteroscopic laser lithotripsy (group 2) . the preoperative-(patient- and stone-related), intraoperative- and postoperative- related parameters that might influence the perioperative course and short-term clinical outcomes were evaluated.

Eligibility criteria:
inclusion criteria: - patients with medium-sized proximal ureteral stones (10-20 mm) situated between the ureteropelvic junction and the top edge of the l5 vertebral body; age 18-65 years exclusion criteria: * pregnancy, bleeding disorders, morbid obesity (bmi \> 35), patients with stenosis of the ureter, history of previous surgery on the ipsilateral ureter, patients with a simultaneous kidney stone requiring surgery, and patients with an active urinary tract infection

Keywords: laser treatment ureteric stones ureteroscope retrograde antegrade
early stockholm obesity prevention program (earlystopp-china)

Conditions: Overweight; Obesity

Summary: early stopp project promotes good health in children from early age by supporting good habits for the whole family. our aim is to see if we can prevent overweight and obesity in children in families where parents are overweight or obese. normal weight parents will also be needed in this study. background: several daily habits lead to less favorable health factors. for example, using the car instead of cycling or walking - leads to less activity in everyday life. individuals also eat more unhealthy foods in larger portions. in combination with genetics, social in heritage and surrounding factors this contributes to increase overweight and obesity among children not only in adults but also in children. good treatment for childhood obesity are lacking, making prevention very important. the earlier good habits are introduced to a child the better it is. in early stopp project we study food, physical activity and sleep habits in the families with a child of one year of age. the height, weight, waist circumference and blood pressure will be recorded in both child and parents. the parents will answer questionnaires about food, physical activity and sleeping habits for both the child and themselves. during the study, the child's physical activity will be measured. based on our observations we aim to develop the preventive strategies for the families with very young children.


Eligibility criteria:
inclusion criteria: * one obese or two overweight parents, 1 year old child exclusion criteria: * weight effecting diseases

Keywords: child overweight child obesity prevention targeted intervention development of overweight
health assessment study (0954-946)

Conditions: Hypertension

Summary: the study will look at the effects of losartan or atenolol on frequency of sexual intercourse in subjects with newly diagnosed mild to moderate hypertension.


Eligibility criteria:
inclusion criteria: * newly diagnosed with mild to moderate hypertension\\ * married male in stable heterosexual relationship * no prior history of sexual dysfunction * satisfied with overall sex life * patient's spouse is in close proximity for the study * has had at least 2 but not more than 10 sexual intercourse events during the 2 week period prior to study start * patient able to visit doctor in the morning of each scheduled visit * able to complete the self administered health assessment questionnaire exclusion criteria: * hypertension due to cancer, history of heart or circulatory problems * history of mental disorder that might impair sexual function * history or presence of drug or alcohol abuse * prior surgery for erectile dysfunction or other urological procedure * no penile implant or assist devices * history of chronic liver disease, history of diabetes * history of severe life-threatening diseases such as, cancer, aids or positive hiv test * subjects with only 1 kidney * mental handicap or legal incapacity
photobiomodulation in individuals with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) is among the most common chronic respiratory diseases (ckd). millions of people of all ages suffer from these diseases. copd is between the fifth and sixth of the leading causes of death in brazil. it generates an inflammatory pulmonary response that is softened by non-curative treatments and that present serious side effects. low intensity laser (lbi) or laser therapy has been used for about 50 years to help the healing process, revealing efficient anti-inflammatory and analgesic responses, as well as experimental models of acute and chronic inflammation. however, little is known about its response in inflammatory lung diseases, especially copd. some reports indicate that laser therapy may interfere positively by relieving clinical signs, the onset, and the final symptoms of pulmonary inflammation. the present project aims to study the effects of lbi on chronic obstructive pulmonary disease in patients with pulmonary processes, determine their mechanisms of action and evaluate its effect on patients' functional capacity.


Eligibility criteria:
inclusion criteria: * individuals of both sexes; * over 18 years of age; * with a diagnosis of chronic obstructive pulmonary disease (copd) for at least 2 years according to the criteria of the clinically stable global initiative for chronic obstructive pulmonary disease (gold), free of disease exacerbation in the last 30 days; * performing routine outpatient treatment with a pulmonologist; * agreement to participate. exclusion criteria: * individuals with other comorbidities, such as: acute lung disease, congestive heart failure, liver failure, pulmonary thromboembolism, acute respiratory distress syndrome, neoplasms, hiv positive, immunodeficiency, blood disorders, septicemia or recent major surgery. * patients with cystic fibrosis and kartagner's syndrome.

Keywords: chronic obstructive pulmonary disease photobiomodulation
gene signatures searching of sensitivity/resistance to neoadjuvant radiotherapy in patients with resectable sts

Conditions: Soft Tissue Sarcomas

Summary: to date, the radiation oncologist are missing biomarkers predictive of response/resistance to rt in order to identify patients who may benefit from rt and personalize the rt schedule. our proposal is to conduct a cohort study aiming at identifying transcriptomic biomarkers predictive of sensitivity and/or resistance to rt in limbs sts patients

whether rt should be performed pre or post-operatively is still a debated question. to date, the radiation oncologist are missing signature of response/resistance to rt in order to identify patients who may benefit from rt and personalize the rt schedule. therefore, predicting the likelihood of response/resistance to rt is essential. the individual exploration with high-throughput approaches will participate in describing biological mechanisms involved in sts tumor cell pan-resistance, thus identifying potential molecular targets that could be inhibited to reverse intrinsic radioresistance. in this context, our proposal is to conduct a cohort study aiming at identifying transcriptomic signature predictive of sensitivity and/or resistance to rt in limbs sts patients.

Eligibility criteria:
inclusion criteria: * male and female ≥ 18 years at time of non-opposition to participate to the study * patient with documented non-opposition to participate to the study. * patient with histologically and cytologically confirmed diagnosis with sts (..) * patient with availability of ffpe tumor block from initial diagnosis biopsy (mandatory) and surgery specimen (optional). * patients with tumor ffpe samples prepared with the last 4 years * patient with evaluable tumor sample meeting the following quality/quantity control criteria (..) exclusion criteria: * patients with metastatic soft tissue sarcoma at diagnosis * patients with exclusive radiotherapy without surgical resection * patients receiving neo adjuvant systemic treatment (chemotherapy, immunotherapy, targeted therapy)
correlation between upper airway endoscopy and physiological traits of obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: objectives to train and test a mathematical model to predict complete concentric collapse at the level of the palate (cccp, primary) and other sites of upper airway collapse (secondary) during drug-induced sleep endoscopy (dise) using the data captured during a diagnostic polysomnography (psg). hypothesis the site, pattern and degree of upper airway collapse is associated with distinct flow features as captured during a baseline psg. study design retrospective trial. study population 200 patients with moderate to severe obstructive sleep apnea (osa, ahi ≥ 15/h) who underwent both a dise and a diagnostic psg at the antwerp university hospital (uza) between january 2018 and december 2020. outcome measures: raw data as captured during a diagnostic psg, including electroencephalography (eeg), flow, electrocardiography (ecg), electromyography (emg), oxygen desaturation and breathing effort. sample size / data analysis data of 200 patients will be retrospectively included into this study protocol. different machine learning techniques will be adopted to select features, train the model and test the model. time schedule january 30, 2021 - november 30, 2021


Eligibility criteria:
inclusion criteria: * 18 years or older. * diagnosis with symptomatic moderate to severe osa (ahi ≥ 15/h). * underwent dise at uza as part of the clinical pathway for non-continuous positive airway pressure (cpap) therapies * underwent a baseline diagnostic psg at uza max 2 years before dise exclusion criteria: * medication use related to sleeping disorders * central sleep apnea syndrome. * medical history of known causes of tiredness by day or severe sleep disruption (insomnia, periodic leg movements, narcolepsy). * seizure disorder. * known medical history of intellectual disability, memory disorders or current psychiatric disorders (psychotic illness, major depression, or acute anxiety attacks as mentioned by the patient). * pregnancy * \<4 h of data recording during the baseline psg night
limited-efficacy testing of sds and nemost for early onset neuromuscular scoliosis

Conditions: Neuromuscular Scoliosis; Distraction System; Growth Friendly System

Summary: the primary aim of this study is to investigate and describe the limited efficacy of the spring distraction system (sds) and bilateral one way rod (nemost) in maintaining curve reduction without repeat lengthening procedures and complications. secondary aims are to describe growth of the instrumented spine, health-related quality of life, and to compare both devices.

several innovative solutions have been developed to treat growing children with a severe scoliosis. one device (sds) was developed internally at the department of orthopaedics umc utrecht in the netherlands. the other device (nemost) was developed at the necker hospital in france. this study is designed as a multicenter, limited-efficacy study using two prospective cohorts according a randomised clinical trial. the study will be performed in two centers (umc utrecht, amsterdam umc and erasmus mc). primary endpoints are the limited-efficacy in terms of maintenance of curve correction and occurrence of saes related to the procedure. these data will be compared to a recently described cohort of patients that received a "standard treatment", the mgcr (skov et al., 2017). secondary endpoints include spinal- and implant growth, patient performance based on the eosq 24 questionnaire and surgical parameters.

Eligibility criteria:
inclusion criteria: * non ambulant * neuromuscular or syndromal scoliosis * progressive scoliosis indicated for bipolar fixation extending to the pelvis * diagnosis of scoliosis before age 10 * patient under 12 and open triradiate cartilage (usually closes around 12 years for girls and 14 years for boys) * main curve proximal end vertebra below th 3 * non rigid curve * patients who have an indication for a primary surgery exclusion criteria: * ambulant * patients with closed triradiate cartilage * patients with a skeletal dysplasia that effects growth (achondroplasia, sed) * patients with a systemic disease which severely influences bone quality e.g. osteogenesis imperfecta, metabolic diseases * patients with soft tissue weakness (ehler danlos, marfan, neurofibromatosis, prader willi) * patients that have a congenital anomaly of the spine of more than 5 vertebrae * patients with an active systemic disease such as jia, hiv, oncologic treatment * patients with a previous surgical fusion of the spine * patients that are expected to be lost to fu due to e.g. likely to immigrate within 1 year. * patients that have had a previous spine surgery.